September 18, 2015
Bristol-Myers Squibb said on September 16 that the US FDA has granted its anti-PD-1 antibody Opdivo (nivolumab) Breakthrough Therapy designation for the potential indication of advanced or metastatic renal cell carcinoma (RCC). Opdivo has been approved in the US, Japan,...read more